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Purpose:  
Triple-negative breast cancer (TNBC) patients with residual disease, following neoadjuvant chemotherapy (NAC) harbor 
higher risk of relapse, and eventual demise compared to those who achieve pathologic complete response. Therefore, the 
purpose of the present study was to characterize the molecular and pathway signatures of TNBC NAC-treated based on 
protein expression analyses and understand the underlying mechanisms of regulation leading to drug resistance. 
Methods:  
I studied 148 TNBC Japanese patients treated with anthracyclines/taxanes-based NAC. Ki67, Topoisomerase IIα 
(TopoIIα), PTEN, p53, Bcl2, vimentin, ABCG2/BCRP1, ABCB1/MDR1 and ABCC1/MRP1, β-catenin, FOXP3, CD8, 
were all immunolocalized in archival materials of the same patients before and after NAC. Tumor infiltrating 
lymphocytes (TILs) were first assessed in the Hematoxylin & Eosin slides. In the in vitro study the multidrug resistance 
proteins (ABCB1/MDR1, ABCG2/BCRP1, ABCC1/MRP1) messenger RNA (mRNA) expression was evaluated by 
real-time polymerase chain reaction under different 
concentrations of chemotherapeutic agents in the mesenchymal stem-like TNBC cell line MDA-MB-231. The 
chemosensitivity of this cell line to Epirubicin, wnt3a and Akt inhibitor (MK2206) was determined using wst-8 
colorimetric assay. PTEN RNA interfering was also used in order to knockdown PTEN expression in the cell line. 
Results:  
The status of vimentin, ABCG2/BCRP1, and increasing labeling index (LI) of TopoIIα and Ki67 and tumor infiltrating 
lymphocytes in biopsy specimens were significantly associated with those who responded to NAC treatment. The relative 
abundance of p53 (p=0.003), ABCC1/MRP1 (p=0.033), ABCB1/MDR1 (p=0.022) and a loss of PTEN (p<0.0001) in 
surgery specimens following treatment were associated with metastasis in lymph nodes, disease free survival or 
lymphovascular invasion. TopoIIα and PTEN status predicted overall survival in the biopsies and ABCC1/MRP1 
predicted disease free survival. In addition, the status of PTEN, ABCC1/MRP1, ABCB1/MDR1, Bcl2 and vimentin in 
surgical specimens was also significantly associated with adverse clinicopathological factors, suggesting that these 
alterations could be responsible for tumor relapse in TNBC patients. The results of in vitro study indicated that 
ABCB1/MDR1 could play possible roles in the development of Epirubicin resistance in TNBC cell line, and that the 
resistance could be overcome by some multidrug resistance-reversing agents including wnt pathway and PI3K/Akt 
pathways inhibitors. 
Conclusion:  
Vimentin, Ki67, TopoIIα, PTEN, ABCC1/MRP1 and TILs status could predict treatment response and/or eventual 
clinical outcomes of TNBC patients NAC-treated. These results could also provide a thought provoking insight into the 
mechanisms of drug resistance and relapse of TNBC patients receiving NAC and offer a more individualized treatment 
option to overcome this resistance but further investigations are required for clarification. 
